

ImmunoPrecise Antibodies Ltd

11:15 23 Sep 2019

ImmunoPrecise Antibodies unveils antibody-engineering platform Abthena

ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF) has launched its Abthena bispecific antibodies platform and its complementary Artemis Intelligence Metadata capabilities.

Bispecific antibodies are an engineered class of antibodies and antibody-like proteins that don't occur naturally. What makes the Abthena bispecifics unique is the ability to bind two different molecules with a single antibody, the company explained in a statement Monday,

This gives them an advantage over naturally-occurring monospecific antibodies in targeting infectious diseases, maximizing payload delivery and improving functional activity toward particularly challenging targets.

READ:ImmunoPrecise reports record fiscal full-year revenue following European expansion

Conversely, Abthena bispecifics can also dual target, which allows for the detection or binding of a target cell type with higher specificity.

ImmunoPrice has designed a platform to discover the wild-type and fully human components of bispecific antibodies, which means it can generate pairs of bound proteins with antibody backbones and the attributes necessary to bind to molecules.

The Abthena platform meshes with Artemis Intelligence Metadata, which offers rapid turnaround on additional algorithmic outputs regarding therapeutic optimization, stability, affinity and manufacturability of the antibodies.

More broadly, ImmunoPrecise is a full-service antibody discovery company. Its goal is to deliver its clients with therapeutically significant custom antibodies that have the greatest probability of ultimately succeeding in clinical trials.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Price: 9.69

Market Cap: \$162.42 m

1 Year Share Price Graph



December 2019 June 2020 December 20

Share Information

Code: IPA

Listing: TSX-V

52 week	High	Low
	15.7	2.5

Sector: Pharma & Biotech

Website: immunoprecise.com

Company Synopsis:

ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).